| Market Cap | 30.16M | P/E | - | EPS this Y | 65.10% | Ern Qtrly Grth | - |
| Income | -74.28M | Forward P/E | -1.43 | EPS next Y | 44.90% | 50D Avg Chg | -7.00% |
| Sales | 20.99M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -45.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -86.00% |
| Recommedations | 3.00 | Quick Ratio | 0.06 | Shares Outstanding | 23.90M | 52W Low Chg | 37.00% |
| Insider Own | 0.52% | ROA | -62.49% | Shares Float | 7.99M | Beta | 1.17 |
| Inst Own | 71.62% | ROE | - | Shares Shorted/Prior | 851.50K/808.77K | Price | 1.27 |
| Gross Margin | 52.58% | Profit Margin | - | Avg. Volume | 704,941 | Target Price | 40.00 |
| Oper. Margin | -255.05% | Earnings Date | - | Volume | 88,972 | Change | -5.93% |
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Vivo Capital VIII, LLC | 10% Owner 10% Owner | Dec 15 | Sell | 0.16 | 575,000 | 92,000 | 280,294 | 12/19/23 |
| SHREWSBURY STEPHEN B | Chief Medical Office.. Chief Medical Officer | Mar 29 | Option | 1.97 | 24,606 | 48,474 | 97,990 | 03/30/22 |
| ADAMS ADRIAN | COB, CEO and Preside.. COB, CEO and President | Aug 19 | Buy | 14.87 | 20,000 | 297,400 | 20,000 | 08/19/21 |